10-Q: Amgen Reports Strong Q3 Growth Amidst Pricing Headwinds

Amgen Inc. announced robust third-quarter and year-to-date financial results, driven by significant product volume growth, despite increasing regulatory and market pricing pressures.

Summary

• Total revenues increased 12% to $9,557 million for the three months ended September 30, 2025, and 10% to $26,885 million for the nine months ended September 30, 2025.
• Product sales grew 12% to $9,137 million for the quarter and 11% to $25,781 million year-to-date, primarily due to 14% volume growth in both periods.
• Net income rose 14% to $3,216 million for the quarter and a substantial 84% to $6,378 million year-to-date.
• Diluted Earnings Per Share (EPS) increased 14% to $5.93 for the quarter and 84% to $11.77 year-to-date.
• Operating income saw a 23% increase to $2,526 million for the quarter and a 29% increase to $6,360 million year-to-date.
• Research and Development (R&D) expenses increased 31% to $1,900 million for the quarter and 21% to $5,130 million year-to-date, driven by investments in Later-Stage Clinical Programs, including MariTide.
• The effective tax rate increased to 18.0% for the quarter (from 8.7% in 2024) and 14.5% year-to-date (from 9.5% in 2024), primarily due to changes in earnings mix and lower amortization expense from acquired inventory.
• Otezla incurred intangible asset impairment charges of $400 million in Q3 2025 and $1.2 billion year-to-date, following its selection for Medicare price setting effective 2027.
• Long-term debt decreased from $56,549 million at December 31, 2024, to $52,434 million at September 30, 2025, with $5.0 billion in debt repayments year-to-date.
• Cash and cash equivalents stood at $9,445 million as of September 30, 2025, down from $11,973 million at December 31, 2024.

Sentiment

Score: 7

Explanation: Amgen demonstrates strong financial performance with robust revenue and earnings growth, driven by key product volumes and strategic debt reduction. Recent positive developments include expanded Repatha approval and a new TEZSPIRE indication. However, significant headwinds persist, including substantial Medicare price setting impacts on ENBREL and Otezla, ongoing biosimilar competition for major products like Prolia and XGEVA, and a large, unresolved IRS tax dispute with billions in potential liabilities. The increasing R&D spend and rising effective tax rate also warrant attention. While the company is profitable and managing its capital effectively, these considerable risks and pricing pressures create uncertainty.

Positives

• Total revenues increased 12% for the three months and 10% for the nine months ended September 30, 2025, demonstrating strong top-line growth.
• Product sales volume grew by 14% for both the three and nine months ended September 30, 2025, indicating healthy demand for key products.
• Net income surged 14% for the quarter and an impressive 84% year-to-date, reflecting improved profitability.
• Diluted EPS also saw significant increases of 14% for the quarter and 84% year-to-date.
• Operating income increased by 23% for the quarter and 29% year-to-date, showcasing operational efficiency.
• Cost of sales decreased as a percentage of total revenues (32.2% in Q3 2025 vs. 38.9% in Q3 2024), driven by lower amortization from acquired inventory and manufacturing costs.
• Other income, net, increased significantly due to higher net unrealized gains on equity investments, primarily BeOne Medicines Ltd., whose fair value increased from $3.5 billion to $6.5 billion.
• Debt reduction efforts are ongoing, with $5.0 billion in debt repayments year-to-date 2025, leading to a decrease in long-term debt.
• Repatha's FDA approval was broadened to include adults at increased risk for major adverse cardiovascular events (MACE), and its Phase 3 VESALIUS-CV trial met dual primary endpoints, showing significant MACE risk reduction.
• TEZSPIRE received FDA approval for add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older.
• Confidential settlement agreements were reached in patent litigation with Samsung Bioepis and Biocon Biologics regarding denosumab biosimilar products in the United States, allowing biosimilar launches while affirming Amgen's patent validity.
• The Board of Directors declared a quarterly cash dividend of $2.38 per share, representing a 6% increase over the quarterly dividends paid in 2024.

Negatives

• ENBREL sales decreased 30% for the quarter and 26% year-to-date, primarily due to a 38% lower net selling price resulting from the U.S. Medicare Part D redesign and increased 340B Program mix.
• KYPROLIS sales decreased 5% for the quarter and 6% year-to-date, attributed to increased competition.
• Otezla incurred significant intangible asset impairment charges of $400 million in Q3 2025 and $1.2 billion year-to-date, following its selection by CMS for Medicare price setting effective January 1, 2027.
• Cash and cash equivalents decreased by $2,528 million from December 31, 2024, to September 30, 2025.
• R&D expenses increased substantially by 31% for the quarter and 21% year-to-date, reflecting higher investments in Later-Stage Clinical Programs.
• The effective tax rate increased significantly for both the three and nine months ended September 30, 2025, compared to the prior year periods.
• Sales erosion is expected for Prolia and XGEVA due to biosimilar competition, with patents expiring in the U.S. in February 2025 and in select European countries in November 2025.
• The FORTITUDE-102 Phase 1b/3 study of bemarituzumab plus chemotherapy and nivolumab in first-line gastric cancer was stopped in November 2025.
• Ongoing legal proceedings, including a major IRS tax dispute totaling approximately $8.7 billion in additional federal tax and penalties for 2010-2015, pose significant financial uncertainty.

Risks

• Sales depend on coverage and reimbursement from government and commercial third-party payers, which are subject to cost containment measures and significant pricing pressures.
• The Inflation Reduction Act (IRA) will negatively affect the business through mandatory Medicare price setting (ENBREL in 2026, Otezla in 2027), Medicare Part D redesign, and inflation penalties.
• The One Big Beautiful Bill Act (OB3) enacted on July 4, 2025, includes changes to Medicare, Medicaid, and Affordable Care Act policies that may adversely affect product coverage and reimbursement.
• The Most-Favored-Nations (MFN) Prescription Drug Pricing Executive Order and the July MFN Letter aim to use international price benchmarks and could lead to lower U.S. drug prices.
• State-level actions, including Prescription Drug Affordability Boards (PDABs) and drug importation programs, are increasing pricing pressure; Colorado's PDAB set an Upper Payment Limit (UPL) for ENBREL substantially lower than its wholesale acquisition cost, effective January 1, 2027.
• Inappropriate expanded utilization of the 340B Program continues to negatively impact product sales and profitability.
• Commercial payer actions, such as benefit plan changes, high deductibles, increased co-pays, and restrictions on access (e.g., Step Therapy, prior authorization), limit patient affordability and product use.
• Consolidation among health insurers, Pharmacy Benefit Managers (PBMs), and integrated healthcare delivery systems increases their negotiating leverage, leading to greater price discounts and rebates.
• Government and commercial payer actions outside the U.S. are expected to intensify pressures to decrease drug expenditures and reduce intellectual property protections, including the EU's review of pharmaceutical legislation.
• Global economic conditions, including inflation, fluctuating interest rates, and financial system instability, may negatively affect the business and magnify other risks.
• Tariffs and trade protection measures (e.g., universal 10% tariff, July Tariff EOs, EU trade framework, China's tariffs, potential sector-specific tariffs up to 200% on pharmaceuticals, 100% tariff on branded products without U.S. manufacturing) are expected to increase manufacturing and operating expenses and disrupt supply chains.
• The ongoing U.S. federal government shutdown has disrupted, and may continue to disrupt, federal agency operations, government contract negotiations, and regulatory activities, including FDA review processes.
• The company faces significant tax litigation with the IRS for the years 2010-2012 and 2013-2015, with proposed additional federal taxes of approximately $3.6 billion and $5.1 billion, respectively, plus $2.0 billion in penalties for 2013-2015.
• Market fluctuations could lead to impairments in the significant portfolio of equity investments, including those in BeOne and Neumora.
• Reliance on major multi-national financial institutions for cash and cash equivalents exposes the company to risks in case of institutional failure, potentially delaying access to uninsured funds.

Future Outlook

Amgen expects continued volume growth from certain brands for the remainder of 2025, though this will be partially offset by net selling price declines. Further declines in Otezla's net selling price are anticipated starting in 2027 due to Medicare price setting. Sales erosion for Prolia and XGEVA is expected from biosimilar competition. The company plans to continue increasing R&D spend on Later-Stage Clinical Programs and estimates full-year 2025 capital project investments to be between $2.2 billion and $2.3 billion. Amgen intends to continue investing in its business, reducing debt, and returning capital to stockholders through dividends and stock repurchases, confident in its future cash flows despite an accumulated deficit. A decision on the significant IRS tax dispute is not expected before the second half of 2026, and further IRS audits for 2019-2022 are anticipated to begin in 2025 or early 2026.

Management Comments

• We helped launch the biotechnology industry more than 40 years ago and have grown to be one of the worlds leading independent biotechnology companies.
• Our robust pipeline includes potential first-in-class medicines at all stages of development.
• We firmly believe that the IRS positions set forth in the 2010-2012 and 2013-2015 Notices are without merit.
• We intend to continue investing in our business while reducing our debt and returning capital to stockholders through the payment of cash dividends and stock repurchases.
• This reflects our desire to optimize our cost of capital and our confidence in the future cash flows of our business.
• Our accumulated deficit is not anticipated to affect our future ability to operate, repurchase stock, pay dividends or repay our debt given our expected continued profitability and strong financial position.

Industry Context

The biotechnology industry continues to face significant challenges from cost containment measures and pricing pressures, particularly in the U.S. with the implementation of the Inflation Reduction Act (IRA) and various state-level drug pricing initiatives like PDABs. Global macroeconomic conditions, including inflation and geopolitical tensions, are increasing operating expenses and creating supply chain uncertainties. Biosimilar competition is intensifying, impacting sales of established products. Internationally, governments are also pursuing measures to reduce drug expenditures and potentially reduce intellectual property protections, as seen with the EU's pharmaceutical legislation review. Consolidation among health insurers and PBMs further increases their negotiating leverage over pharmaceutical manufacturers.

Comparison to Industry Standards

• Amgen's Repatha is broadening its approved use, competing in the cardiovascular disease market against other therapies, with its Phase 3 VESALIUS-CV trial demonstrating significant MACE risk reduction.
• TEZSPIRE's new FDA approval for chronic rhinosinusitis with nasal polyps expands its market presence in respiratory diseases, where it competes with other biologics.
• The company is actively engaged in patent litigation with competitors like Sanofi, Regeneron, Samsung Bioepis, Shanghai Henlius Biotech, Hikma Pharmaceuticals, Biocon Biologics, and Amneal Pharmaceuticals over key products such as Repatha, Prolia, XGEVA, PAVBLU, and KYPROLIS, reflecting the highly competitive intellectual property landscape in the biopharmaceutical sector.
• Amgen's collaboration with AstraZeneca for TEZSPIRE and its equity investment in Neumora Therapeutics highlight strategic partnerships common in the industry for R&D and commercialization.

Legal Proceedings

• **Repatha Patent Litigation (EU Unified Patent Court)**: The Dusseldorf Local Division stayed Sanofi's lawsuit against Amgen, pending an appeal decision. Oral arguments were heard on Amgen's appeal to set aside a decision to revoke its European Patent No. 3,666,797. Amgen and Sanofi/Regeneron filed appeals regarding the validity and infringement of European Patent No. 3,536,712.
• **Prolia/XGEVA Biologics Price Competition and Innovation Act (BPCIA) Litigation**: Amgen reached confidential settlement agreements with Samsung Bioepis and Biocon Biologics, allowing them to launch denosumab biosimilar products in the U.S. while affirming Amgen's patent validity. Amgen is engaged in ongoing litigation with Shanghai Henlius Biotech Inc. et al. and Hikma Pharmaceuticals USA Inc. et al. regarding denosumab biosimilars. A new case schedule was issued for the multidistrict litigation, but no claim construction hearing or trial date has been set.
• **PAVBLU (aflibercept-ayyh) Patent Litigation**: Amgen responded to Regeneron's complaint, denying infringement and asserting counterclaims for declaratory judgment, Sherman Act monopolization, and unlawful/unfair practices. A scheduling order was entered, with a claim construction hearing set for November 23, 2026.
• **KYPROLIS (carfilzomib) Abbreviated New Drug Application (ANDA) Patent Litigation**: A confidential settlement was reached with Somerset Therapeutics, LLC, affirming infringement of U.S. Patent No. 7,737,112. Onyx Therapeutics (an Amgen subsidiary) filed a lawsuit against Amneal Pharmaceuticals seeking to prevent FDA approval of a generic KYPROLIS until patent expiration.
• **Antitrust Actions**: In the CareFirst of Maryland Antitrust Class Action, the court dismissed some claims but allowed others to proceed. Amgen filed a reply in the Sandoz Inc. Antitrust Action. Several similar antitrust cases filed in California Superior Court by Centene, Humana, Molina Healthcare, and Blue Cross Blue Shield entities were voluntarily dismissed without prejudice.
• **U.S. Tax Litigation and Related Matters**: Amgen is contesting IRS notices for 2010-2012 and 2013-2015, seeking approximately $3.6 billion and $5.1 billion in additional federal tax, respectively, plus $2.0 billion in penalties for 2013-2015. The consolidated cases concluded trial in January 2025, with oral arguments in July 2025 and post-trial reply briefs in October 2025. A decision is expected no earlier than the second half of 2026. The IRS is also examining 2016-2018 and is expected to audit 2019-2022.
• **Securities Class Action Litigation (Roofers Local No. 149 Pension Fund)**: Deadlines were extended, with class certification briefing due by April 24, 2026, and summary judgment motions by December 21, 2026.
• **ChemoCentryx, Inc. Securities Matters**: Summary judgment was granted to defendants, including ChemoCentryx, in August 2025. The lead plaintiff filed a notice of appeal in September 2025.

Related Party Transactions

• A Letter Agreement dated August 11, 2025, was executed between Amgen Inc. and BeOne Medicines I GmbH and BeOne Medicines Ltd. (formerly BeiGene), modifying certain rights related to a 'Distracting Target' and 'Distracting Program Restrictions' under their Collaboration Agreement. This includes waivers for certain programs, an updated definition of 'Distracting Product', discussions for BLINCYTO development in specific indications, and Amgen gaining unrestricted rights to exploit a previously terminated product, [*], free from obligations to BeOne. BeOne also confirmed UPLIZNA is not a Distracting Product.

Stakeholder Impact

• **Shareholders**: Positive impact from strong revenue, net income, and EPS growth, along with increased dividends and ongoing debt reduction. Potential negative impact from significant IRS tax liabilities, ongoing drug pricing pressures, and market volatility affecting equity investments.
• **Customers/Patients**: Positive impact from expanded Repatha approval and a new TEZSPIRE indication. Potential negative impact from Medicare price setting for ENBREL and Otezla, which could lead to lower reimbursement and potentially affect access or affordability, as well as restrictions imposed by PBMs and state-level policies.
• **Employees**: No direct impact on employment or compensation explicitly mentioned, but increased R&D investments suggest continued activity in those areas.
• **Suppliers/Partners**: The collaboration agreement with BeOne Medicines has been modified, impacting future development and commercialization rights. Potential negative impact on sourcing costs and supply chain efficiency due to tariffs and trade protection measures.
• **Creditors**: Positive impact from consistent debt repayments and compliance with financial covenants, indicating sound financial management.

Next Steps

• Volume growth from certain brands is expected to be partially offset by net selling price declines for the remainder of 2025.
• Further declines in Otezla's net selling price are expected starting in 2027 due to Medicare price setting.
• The company plans to continue growing R&D spend on Later-Stage Clinical Programs.
• A decision from the U.S. Tax Court on the IRS disputes is expected no earlier than the second half of 2026.
• The IRS is expected to begin its audit of 2019-2022 in 2025 or early 2026.
• Full-year 2025 investments in capital projects are estimated to be in the range of $2.2 billion to $2.3 billion.
• The lead plaintiff's opening brief in the ChemoCentryx securities matter appeal is due December 5, 2025.
• A claim construction hearing for the PAVBLU patent litigation is scheduled for November 23, 2026.
• Class certification briefing for the Roofers Local No. 149 Pension Fund securities class action will be completed by April 24, 2026, with summary judgment motions due by December 21, 2026.

Key Dates

Recommendation

Amgen demonstrates strong financial performance with robust revenue and earnings growth, driven by key product volumes and strategic debt reduction. Recent positive developments include expanded Repatha approval and a new TEZSPIRE indication. However, significant headwinds persist, including substantial Medicare price setting impacts on ENBREL and Otezla, ongoing biosimilar competition for major products like Prolia and XGEVA, and a large, unresolved IRS tax dispute with billions in potential liabilities. The increasing R&D spend and rising effective tax rate also warrant attention. While the company is profitable and managing its capital effectively, these considerable risks and pricing pressures create uncertainty, suggesting a 'hold' position until there is greater clarity on the resolution of the tax dispute and the full impact of drug pricing regulations.

Keywords

Biotechnology, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Product Sales, Revenue Growth, Earnings Per Share, R&D Expenses, Drug Pricing, Medicare, IRA, Biosimilars, Patent Litigation, Tax Litigation, Global Economy, Tariffs, Repatha, TEZSPIRE, ENBREL, Otezla, BLINCYTO, XGEVA, Prolia, KYPROLIS, BeOne Medicines